An FDA inspection of this Ranbaxy facility in Toansa, Punjab, India, in 2014, revealed drug quality testing violations, resulting in the FDA prohibiting Ranbaxy from marketing drugs in the U.S. that were manufactured at this plant. (Dhiraj Singh/Getty Images)
